Riboflavin and Folic Acid: study protocols
7 study groups took Riboflavin together with Folic Acid. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Riboflavin
7 study groups in 5 studies say how much Riboflavin participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 1 mg to 2.5 mg, 57% of 7 study groups.
| Daily dose | Study groups |
|---|---|
| 1 mg to 2.5 mg | 4 |
| 2.5 mg to 5 mg | 1 |
| 5 mg to 10 mg | 0 |
| 10 mg to 25 mg | 2 |
Dose per serving from research: Folic Acid
7 study groups in 5 studies say how much Folic Acid participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mcg to 500 mcg, 57% of 7 study groups.
| Daily dose | Study groups |
|---|---|
| 250 mcg to 500 mcg | 4 |
| 500 mcg to 1 mg | 3 |
Commonly used together
7 of 7 study groups took Riboflavin and Folic Acid with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Vitamin B12 | 7 |
| Vitamin B6 | 6 |
| Thiamine | 4 |
| Vitamin C | 4 |
| Vitamin E | 4 |
| Zinc | 4 |
| Iron | 3 |
| Vitamin A | 3 |
| Vitamin D | 3 |
7 study groups
| Study | ||||
|---|---|---|---|---|
| Effects of maternal micronutrient supplementation on fetal loss and infant mortality: a cluster-randomized trial in Nepal 2003 · Multiple micronutrients · Pregnant women in rural Nepal | 1.8 mg | 400 mcg | — | — |
| Multivitamin supplementation of HIV-positive women during pregnancy reduces hypertension 2005 · Multivitamin plus vitamin A · HIV-positive pregnant Tanzanian women | 20 mg | 800 mcg | — | — |
| Multivitamin supplementation of HIV-positive women during pregnancy reduces hypertension 2005 · Multivitamin without vitamin A · HIV-positive pregnant Tanzanian women | 20 mg | 800 mcg | — | — |
| Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Prespecified secondary analysis of the NiPPeR double-blind randomized controlled trial 2023 · intervention · Women planning pregnancy; generally healthy, recruited before conception | 1.8 mg | 400 mcg | — | 870 |
| A novel nutritional supplement to reduce plasma homocysteine in nonpregnant women: A randomised controlled trial in The Gambia 2019 · UNIMMAP tablet · Nonpregnant, non-lactating healthy women aged 18–45 years in West Kiang, The Gambia; women of reproductive age with common micronutrient deficiencies in the population | 1.4 mg | 400 mcg | 12 weeks | 105 |
| A novel nutritional supplement to reduce plasma homocysteine in nonpregnant women: A randomised controlled trial in The Gambia 2019 · drink powder · Nonpregnant, non-lactating healthy women aged 18–45 years in West Kiang, The Gambia; women of reproductive age with common micronutrient deficiencies in the population | 2.8 mg | 800 mcg | 12 weeks | 93 |
| Nutraceutical approaches to homocysteine lowering in hypertensive subjects at low cardiovascular risk: a multicenter, randomized clinical trial 2016 · Normocis 400® group · Adults with stage 1 essential hypertension and hyper-homocysteinemia (HCys ≥15 μmol/L), without a history of cardiovascular or cerebrovascular disease; mean age 62.8 years, 63.5% male | 2.4 mg | 400 mcg | 60 days | 52 |